Yelena Y. Janjigian, Salah-Eddin Al-Batran, Zev A. Wainberg, Kei Muro, Daniela Molena, Eric Van Cutsem, Woo Jin Hyung, Lucjan Wyrwicz, Do-Youn Oh, Takeshi Omori, Markus H. Moehler, Marcelo Garrido, Sulene S.C. Oliveira, Moishe Liberman, Victor Castro Oliden, Elizabeth Catherine Smyth, Olivier Serrano, Eric Heilbron, Alejandra Negro, Josep Tabernero. "Event-free survival (EFS) in MATTERHORN: A randomized, phase 3 study of durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel chemotherapy (FLOT) in resectable gastric/gastroesophageal junction cancer (GC/GEJC).." Journal of Clinical Oncology (2025). https://doi.org/10.1200/jco.2025.43.17_suppl.lba5